Unknown

Dataset Information

0

CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy.


ABSTRACT: Personalized cancer vaccines aim to activate and expand cytotoxic antitumor CD8+ T cells to recognize and kill tumor cells. However, the role of CD4+ T cell activation in the clinical benefit of these vaccines is not well defined. We previously established a personalized neoantigen vaccine (PancVAX) for the pancreatic cancer cell line Panc02, which activates tumor-specific CD8+ T cells but required combinatorial checkpoint modulators to achieve therapeutic efficacy. To determine the effects of neoantigen-specific CD4+ T cell activation, we generated a vaccine (PancVAX2) targeting both major histocompatibility complex class I- (MHCI-) and MHCII-specific neoantigens. Tumor-bearing mice vaccinated with PancVAX2 had significantly improved control of tumor growth and long-term survival benefit without concurrent administration of checkpoint inhibitors. PancVAX2 significantly enhanced priming and recruitment of neoantigen-specific CD8+ T cells into the tumor with lower PD-1 expression after reactivation compared with the CD8+ vaccine alone. Vaccine-induced neoantigen-specific Th1 CD4+ T cells in the tumor were associated with decreased Tregs. Consistent with this, PancVAX2 was associated with more proimmune myeloid-derived suppressor cells and M1-like macrophages in the tumor, demonstrating a less immunosuppressive tumor microenvironment. This study demonstrates the biological importance of prioritizing and including CD4+ T cell-specific neoantigens for personalized cancer vaccine modalities.

SUBMITTER: Huff AL 

PROVIDER: S-EPMC10795827 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications


Personalized cancer vaccines aim to activate and expand cytotoxic antitumor CD8+ T cells to recognize and kill tumor cells. However, the role of CD4+ T cell activation in the clinical benefit of these vaccines is not well defined. We previously established a personalized neoantigen vaccine (PancVAX) for the pancreatic cancer cell line Panc02, which activates tumor-specific CD8+ T cells but required combinatorial checkpoint modulators to achieve therapeutic efficacy. To determine the effects of n  ...[more]

Similar Datasets

2023-12-11 | GSE244992 | GEO
| PRJNA1026585 | ENA
| S-EPMC7919731 | biostudies-literature
| S-EPMC5910567 | biostudies-literature
| S-EPMC10219310 | biostudies-literature
| 2305807 | ecrin-mdr-crc
2018-03-01 | GSE93835 | GEO
| S-EPMC10073290 | biostudies-literature
| S-EPMC7201246 | biostudies-literature
| S-EPMC7651423 | biostudies-literature